Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 130 articles:
HTML format
Text format



Single Articles


    January 2017
  1. FAKKERT IE, van der Veer E, Abma EM, Lefrandt JD, et al
    Elevated Bone Turnover Markers after Risk-Reducing Salpingo-Oophorectomy in Women at Increased Risk for Breast and Ovarian Cancer.
    PLoS One. 2017;12:e0169673.
    PubMed     Text format     Abstract available


  2. SEEBACHER V, Reinthaller A, Koelbl H, Concin N, et al
    The Impact of the Duration of Adjuvant Chemotherapy on Survival in Patients with Epithelial Ovarian Cancer - A Retrospective Study.
    PLoS One. 2017;12:e0169272.
    PubMed     Text format     Abstract available


  3. LEE HH, Bellat V, Law B
    Chemotherapy induces adaptive drug resistance and metastatic potentials via phenotypic CXCR4-expressing cell state transition in ovarian cancer.
    PLoS One. 2017;12:e0171044.
    PubMed     Text format     Abstract available


  4. BAI L, Wang H, Wang AH, Zhang LY, et al
    MicroRNA-532 and microRNA-3064 inhibit cell proliferation and invasion by acting as direct regulators of human telomerase reverse transcriptase in ovarian cancer.
    PLoS One. 2017;12:e0173912.
    PubMed     Text format     Abstract available


  5. PRAHM KP, Hogdall C, Karlsen MA, Christensen IJ, et al
    Clinical validation of chemotherapy predictors developed on global microRNA expression in the NCI60 cell line panel tested in ovarian cancer.
    PLoS One. 2017;12:e0174300.
    PubMed     Text format     Abstract available


  6. MA Z, Wang X, He J, Xia J, et al
    Increased expression of protein kinase CK2alpha correlates with poor patient prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0174037.
    PubMed     Text format     Abstract available


  7. COZZI GD, Levinson RT, Toole H, Snyder MR, et al
    Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0175119.
    PubMed     Text format     Abstract available


  8. BRENCICOVA E, Jagger AL, Evans HG, Georgouli M, et al
    Interleukin-10 and prostaglandin E2 have complementary but distinct suppressive effects on Toll-like receptor-mediated dendritic cell activation in ovarian carcinoma.
    PLoS One. 2017;12:e0175712.
    PubMed     Text format     Abstract available


  9. GRAUMANN R, Di Capua GA, Oyarzun JE, Vasquez MA, et al
    Expression of teneurins is associated with tumor differentiation and patient survival in ovarian cancer.
    PLoS One. 2017;12:e0177244.
    PubMed     Text format     Abstract available


  10. CHEN WC, Qiu JT, Lai CH, Huang HJ, et al
    Outcomes and prognoses of patients with ovarian cancer using bevacizumab: 6-year experience in a tertiary care hospital of northern Taiwan.
    PLoS One. 2017;12:e0175703.
    PubMed     Text format     Abstract available


  11. LIU C, Zhang Y, Jiang H, Wu H, et al
    Association between social support and post-traumatic stress disorder symptoms among Chinese patients with ovarian cancer: A multiple mediation model.
    PLoS One. 2017;12:e0177055.
    PubMed     Text format     Abstract available



  12. Correction: Blood type, ABO genetic variants, and ovarian cancer survival.
    PLoS One. 2017;12:e0178965.
    PubMed     Text format     Abstract available


  13. STAFFORD JL, Dyson G, Levin NK, Chaudhry S, et al
    Reanalysis of BRCA1/2 negative high risk ovarian cancer patients reveals novel germline risk loci and insights into missing heritability.
    PLoS One. 2017;12:e0178450.
    PubMed     Text format     Abstract available


  14. ZHANG W, Su J, Xu H, Yu S, et al
    Dicumarol inhibits PDK1 and targets multiple malignant behaviors of ovarian cancer cells.
    PLoS One. 2017;12:e0179672.
    PubMed     Text format     Abstract available


  15. BJERSAND K, Seidal T, Sundstrom-Poromaa I, Akerud H, et al
    The clinical and prognostic correlation of HRNPM and SLC1A5 in pathogenesis and prognosis in epithelial ovarian cancer.
    PLoS One. 2017;12:e0179363.
    PubMed     Text format     Abstract available


  16. SIEBENKAS C, Chiappinelli KB, Guzzetta AA, Sharma A, et al
    Inhibiting DNA methylation activates cancer testis antigens and expression of the antigen processing and presentation machinery in colon and ovarian cancer cells.
    PLoS One. 2017;12:e0179501.
    PubMed     Text format     Abstract available


  17. WAN X, Bovornchutichai P, Cui Z, O'Neill E, et al
    Morphological analysis of human umbilical vein endothelial cells co-cultured with ovarian cancer cells in 3D: An oncogenic angiogenesis assay.
    PLoS One. 2017;12:e0180296.
    PubMed     Text format     Abstract available


  18. CHAO TK, Huang TS, Liao YP, Huang RL, et al
    Pyruvate kinase M2 is a poor prognostic marker of and a therapeutic target in ovarian cancer.
    PLoS One. 2017;12:e0182166.
    PubMed     Text format     Abstract available


  19. LANDSKRON J, Kraggerud SM, Wik E, Dorum A, et al
    C77G in PTPRC (CD45) is no risk allele for ovarian cancer, but associated with less aggressive disease.
    PLoS One. 2017;12:e0182030.
    PubMed     Text format     Abstract available


  20. PAULLIN T, Powell C, Menzie C, Hill R, et al
    Spheroid growth in ovarian cancer alters transcriptome responses for stress pathways and epigenetic responses.
    PLoS One. 2017;12:e0182930.
    PubMed     Text format     Abstract available


  21. ROZENBLUM E, Sotelo-Silveira JR, Kim GY, Zhu JY, et al
    Novel near-diploid ovarian cancer cell line derived from a highly aneuploid metastatic ovarian tumor.
    PLoS One. 2017;12:e0182610.
    PubMed     Text format     Abstract available


  22. PETERS IT, van Zwet EW, Smit VT, Liefers GJ, et al
    Prevalence and Risk Factors of Ovarian Metastases in Breast Cancer Patients < 41 Years of Age in the Netherlands: A Nationwide Retrospective Cohort Study.
    PLoS One. 2017;12:e0168277.
    PubMed     Text format     Abstract available


  23. ZHU J, Wen H, Ju X, Bi R, et al
    Clinical Significance of Programmed Death Ligand1 and Intra-Tumoral CD8+ T Lymphocytes in Ovarian Carcinosarcoma.
    PLoS One. 2017;12:e0170879.
    PubMed     Text format     Abstract available


  24. SEEBACHER V, Aust S, D'Andrea D, Grimm C, et al
    Development of a tool for prediction of ovarian cancer in patients with adnexal masses: Value of plasma fibrinogen.
    PLoS One. 2017;12:e0182383.
    PubMed     Text format     Abstract available


  25. HAIMOVICH JS, Venkatesh AK, Shojaee A, Coppi A, et al
    Discovery of temporal and disease association patterns in condition-specific hospital utilization rates.
    PLoS One. 2017;12:e0172049.
    PubMed     Text format     Abstract available


  26. JIA ZH, Jia Y, Guo FJ, Chen J, et al
    Phosphorylation of STAT3 at Tyr705 regulates MMP-9 production in epithelial ovarian cancer.
    PLoS One. 2017;12:e0183622.
    PubMed     Text format     Abstract available


  27. CHUNG YS, Kim YJ, Lee I, Lee JY, et al
    Impact of neoadjuvant chemotherapy and postoperative adjuvant chemotherapy cycles on survival of patients with advanced-stage ovarian cancer.
    PLoS One. 2017;12:e0183754.
    PubMed     Text format     Abstract available


  28. ZHANG H, Lu J, Lu Y, Zhou J, et al
    Prognostic significance and predictors of the system inflammation score in ovarian clear cell carcinoma.
    PLoS One. 2017;12:e0177520.
    PubMed     Text format     Abstract available


  29. ROSSO M, Majem B, Devis L, Lapyckyj L, et al
    E-cadherin: A determinant molecule associated with ovarian cancer progression, dissemination and aggressiveness.
    PLoS One. 2017;12:e0184439.
    PubMed     Text format     Abstract available


  30. AYYAGARI VN, Diaz-Sylvester PL, Hsieh TJ, Brard L, et al
    Evaluation of the cytotoxicity of the Bithionol-paclitaxel combination in a panel of human ovarian cancer cell lines.
    PLoS One. 2017;12:e0185111.
    PubMed     Text format     Abstract available


  31. GRANATA V, Fusco R, Catalano O, Avallone A, et al
    Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases.
    PLoS One. 2017;12:e0179951.
    PubMed     Text format     Abstract available


  32. YANAGIDA S, Anglesio MS, Nazeran TM, Lum A, et al
    Clinical and genetic analysis of recurrent adult-type granulosa cell tumor of the ovary: Persistent preservation of heterozygous c.402C>G FOXL2 mutation.
    PLoS One. 2017;12:e0178989.
    PubMed     Text format     Abstract available


  33. LIN KT, Sun SP, Wu JI, Wang LH, et al
    Low-dose glucocorticoids suppresses ovarian tumor growth and metastasis in an immunocompetent syngeneic mouse model.
    PLoS One. 2017;12:e0178937.
    PubMed     Text format     Abstract available


  34. SUNG PL, Wen KC, Chen YJ, Chao TC, et al
    The frequency of cancer predisposition gene mutations in hereditary breast and ovarian cancer patients in Taiwan: From BRCA1/2 to multi-gene panels.
    PLoS One. 2017;12:e0185615.
    PubMed     Text format     Abstract available


  35. ZHU XM, Sun WF
    Association between matrix metalloproteinases polymorphisms and ovarian cancer risk: A meta-analysis and systematic review.
    PLoS One. 2017;12:e0185456.
    PubMed     Text format     Abstract available


  36. TAO X, Chen L, Ge S, Cai L, et al
    Weigh the pros and cons to ovarian reserve before stripping ovarian endometriomas prior to IVF/ICSI: A meta-analysis.
    PLoS One. 2017;12:e0177426.
    PubMed     Text format     Abstract available


  37. HARTER P, Hauke J, Heitz F, Reuss A, et al
    Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
    PLoS One. 2017;12:e0186043.
    PubMed     Text format     Abstract available


  38. GUO Z, Wang X, Cheng D, Xia Z, et al
    Correction: PD-1 Blockade and OX40 Triggering Synergistically Protects against Tumor Growth in a Murine Model of Ovarian Cancer.
    PLoS One. 2017;12:e0186965.
    PubMed     Text format     Abstract available


  39. VALIANATOS G, Valcikova B, Growkova K, Verlande A, et al
    A small molecule drug promoting miRNA processing induces alternative splicing of MdmX transcript and rescues p53 activity in human cancer cells overexpressing MdmX protein.
    PLoS One. 2017;12:e0185801.
    PubMed     Text format     Abstract available


  40. FORNARO L, Vivaldi C, Lin D, Xue H, et al
    Prognostic relevance of a T-type calcium channels gene signature in solid tumours: A correlation ready for clinical validation.
    PLoS One. 2017;12:e0182818.
    PubMed     Text format     Abstract available


  41. YANG L, Zhang B, Xing G, Du J, et al
    Neoadjuvant chemotherapy versus primary debulking surgery in advanced epithelial ovarian cancer: A meta-analysis of peri-operative outcome.
    PLoS One. 2017;12:e0186725.
    PubMed     Text format     Abstract available


  42. GENG X, Liu Y, Diersch S, Kotzsch M, et al
    Clinical relevance of kallikrein-related peptidase 9, 10, 11, and 15 mRNA expression in advanced high-grade serous ovarian cancer.
    PLoS One. 2017;12:e0186847.
    PubMed     Text format     Abstract available


  43. QIN L, Li T, Liu Y
    High SLC4A11 expression is an independent predictor for poor overall survival in grade 3/4 serous ovarian cancer.
    PLoS One. 2017;12:e0187385.
    PubMed     Text format     Abstract available


  44. CHESNAIS M, Lecuru F, Mimouni M, Ngo C, et al
    A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
    PLoS One. 2017;12:e0187245.
    PubMed     Text format     Abstract available


    January 2016
  45. HONG H, Brown CE, Ostberg JR, Priceman SJ, et al
    L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice.
    PLoS One. 2016;11:e0146885.
    PubMed     Text format     Abstract available


  46. VIDAL F, Guerby P, Luyckx M, Haddad P, et al
    Are Early Relapses in Advanced-Stage Ovarian Cancer Doomed to a Poor Prognosis?
    PLoS One. 2016;11:e0147787.
    PubMed     Text format     Abstract available


  47. WILLIS S, Villalobos VM, Gevaert O, Abramovitz M, et al
    Single Gene Prognostic Biomarkers in Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0149183.
    PubMed     Text format     Abstract available


  48. HUA X, Yu L, You R, Yang Y, et al
    Association among Dietary Flavonoids, Flavonoid Subclasses and Ovarian Cancer Risk: A Meta-Analysis.
    PLoS One. 2016;11:e0151134.
    PubMed     Text format     Abstract available


  49. LEHTINEN L, Vesterkvist P, Roering P, Korpela T, et al
    REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker.
    PLoS One. 2016;11:e0151590.
    PubMed     Text format     Abstract available


  50. XIA Y, Chang T, Wang Y, Liu Y, et al
    Correction: YAP Promotes Ovarian Cancer Cell Tumorigenesis and Is Indicative of a Poor Prognosis for Ovarian Cancer Patients.
    PLoS One. 2016;11:e0152712.
    PubMed     Text format     Abstract available


  51. RAHMAN MA, Ramli F, Karimian H, Dehghan F, et al
    Artonin E Induces Apoptosis via Mitochondrial Dysregulation in SKOV-3 Ovarian Cancer Cells.
    PLoS One. 2016;11:e0151466.
    PubMed     Text format     Abstract available


  52. ZUBERI M, Khan I, Mir R, Gandhi G, et al
    Utility of Serum miR-125b as a Diagnostic and Prognostic Indicator and Its Alliance with a Panel of Tumor Suppressor Genes in Epithelial Ovarian Cancer.
    PLoS One. 2016;11:e0153902.
    PubMed     Text format     Abstract available


  53. CHOI JI, Park SH, Lee HJ, Lee DW, et al
    Inhibition of Phospho-S6 Kinase, a Protein Involved in the Compensatory Adaptive Response, Increases the Efficacy of Paclitaxel in Reducing the Viability of Matrix-Attached Ovarian Cancer Cells.
    PLoS One. 2016;11:e0155052.
    PubMed     Text format     Abstract available


  54. ALAEE M, Danesh G, Pasdar M
    Plakoglobin Reduces the in vitro Growth, Migration and Invasion of Ovarian Cancer Cells Expressing N-Cadherin and Mutant p53.
    PLoS One. 2016;11:e0154323.
    PubMed     Text format     Abstract available


  55. NORDIN N, Fadaeinasab M, Mohan S, Mohd Hashim N, et al
    Pulchrin A, a New Natural Coumarin Derivative of Enicosanthellum pulchrum, Induces Apoptosis in Ovarian Cancer Cells via Intrinsic Pathway.
    PLoS One. 2016;11:e0154023.
    PubMed     Text format     Abstract available


  56. PAINE MR, Kim J, Bennett RV, Parry RM, et al
    Whole Reproductive System Non-Negative Matrix Factorization Mass Spectrometry Imaging of an Early-Stage Ovarian Cancer Mouse Model.
    PLoS One. 2016;11:e0154837.
    PubMed     Text format     Abstract available


  57. MACLEAN JA 2ND, King ML, Okuda H, Hayashi K, et al
    WNT7A Regulation by miR-15b in Ovarian Cancer.
    PLoS One. 2016;11:e0156109.
    PubMed     Text format     Abstract available


  58. MARTIN SD, Brown SD, Wick DA, Nielsen JS, et al
    Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines.
    PLoS One. 2016;11:e0155189.
    PubMed     Text format     Abstract available


  59. ZHOU Y, Xu X, Lv H, Wen Q, et al
    The Long Noncoding RNA MALAT-1 Is Highly Expressed in Ovarian Cancer and Induces Cell Growth and Migration.
    PLoS One. 2016;11:e0155250.
    PubMed     Text format     Abstract available


  60. FENG Z, Wen H, Bi R, Ju X, et al
    Preoperative Neutrophil-to-Lymphocyte Ratio as a Predictive and Prognostic Factor for High-Grade Serous Ovarian Cancer.
    PLoS One. 2016;11:e0156101.
    PubMed     Text format     Abstract available


  61. SOSULSKI A, Horn H, Zhang L, Coletti C, et al
    CD44 Splice Variant v8-10 as a Marker of Serous Ovarian Cancer Prognosis.
    PLoS One. 2016;11:e0156595.
    PubMed     Text format     Abstract available


  62. ZHOU Q, Li W, Leng B, Zheng W, et al
    Circulating Cell Free DNA as the Diagnostic Marker for Ovarian Cancer: A Systematic Review and Meta-Analysis.
    PLoS One. 2016;11:e0155495.
    PubMed     Text format     Abstract available


  63. TRACHANA SP, Pilalis E, Gavalas NG, Tzannis K, et al
    The Development of an Angiogenic Protein "Signature" in Ovarian Cancer Ascites as a Tool for Biologic and Prognostic Profiling.
    PLoS One. 2016;11:e0156403.
    PubMed     Text format     Abstract available


  64. BOTESTEANU DA, Lee JM, Levy D
    Modeling the Dynamics of High-Grade Serous Ovarian Cancer Progression for Transvaginal Ultrasound-Based Screening and Early Detection.
    PLoS One. 2016;11:e0156661.
    PubMed     Text format     Abstract available


  65. HELLAND O, Popa M, Bischof K, Gjertsen BT, et al
    The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    PLoS One. 2016;11:e0158208.
    PubMed     Text format     Abstract available


  66. VIGORITO E, Kuchenbaecker KB, Beesley J, Adlard J, et al
    Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers.
    PLoS One. 2016;11:e0158801.
    PubMed     Text format     Abstract available


  67. TAKAHASHI R, Mabuchi S, Kawano M, Sasano T, et al
    Preclinical Investigations of PM01183 (Lurbinectedin) as a Single Agent or in Combination with Other Anticancer Agents for Clear Cell Carcinoma of the Ovary.
    PLoS One. 2016;11:e0151050.
    PubMed     Text format     Abstract available


  68. KIM HJ, Lee SY, Shin YR, Park CS, et al
    The Value of Diffusion-Weighted Imaging in the Differential Diagnosis of Ovarian Lesions: A Meta-Analysis.
    PLoS One. 2016;11:e0149465.
    PubMed     Text format     Abstract available


  69. YOSHIDA M, Taguchi A, Kawana K, Adachi K, et al
    Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
    PLoS One. 2016;11:e0160330.
    PubMed     Text format     Abstract available


  70. CHOWANADISAI W, Messerli SM, Miller DH, Medina JE, et al
    Cisplatin Resistant Spheroids Model Clinically Relevant Survival Mechanisms in Ovarian Tumors.
    PLoS One. 2016;11:e0151089.
    PubMed     Text format     Abstract available


  71. WANG T, Li W, Wu X, Yin B, et al
    Tubo-Ovarian Abscess (with/without Pseudotumor Area) Mimicking Ovarian Malignancy: Role of Diffusion-Weighted MR Imaging with Apparent Diffusion Coefficient Values.
    PLoS One. 2016;11:e0149318.
    PubMed     Text format     Abstract available


  72. PINTO P, Peixoto A, Santos C, Rocha P, et al
    Analysis of Founder Mutations in Rare Tumors Associated With Hereditary Breast/Ovarian Cancer Reveals a Novel Association of BRCA2 Mutations with Ampulla of Vater Carcinomas.
    PLoS One. 2016;11:e0161438.
    PubMed     Text format     Abstract available


  73. TALHOUK A, Kommoss S, Mackenzie R, Cheung M, et al
    Single-Patient Molecular Testing with NanoString nCounter Data Using a Reference-Based Strategy for Batch Effect Correction.
    PLoS One. 2016;11:e0153844.
    PubMed     Text format     Abstract available


  74. SHAH JS, Soon PS, Marsh DJ
    Comparison of Methodologies to Detect Low Levels of Hemolysis in Serum for Accurate Assessment of Serum microRNAs.
    PLoS One. 2016;11:e0153200.
    PubMed     Text format     Abstract available


  75. TUMBARELLO DA, Andrews MR, Brenton JD
    SPARC Regulates Transforming Growth Factor Beta Induced (TGFBI) Extracellular Matrix Deposition and Paclitaxel Response in Ovarian Cancer Cells.
    PLoS One. 2016;11:e0162698.
    PubMed     Text format     Abstract available


  76. XIAO X, Cai F, Niu X, Shi H, et al
    Association between P16INK4a Promoter Methylation and Ovarian Cancer: A Meta-Analysis of 12 Published Studies.
    PLoS One. 2016;11:e0163257.
    PubMed     Text format     Abstract available


  77. LI L, Luo Q, Xie Z, Li G, et al
    Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
    PLoS One. 2016;11:e0163447.
    PubMed     Text format     Abstract available


  78. IGNACIO RM, Kabir SM, Lee ES, Adunyah SE, et al
    NF-kappaB-Mediated CCL20 Reigns Dominantly in CXCR2-Driven Ovarian Cancer Progression.
    PLoS One. 2016;11:e0164189.
    PubMed     Text format     Abstract available


  79. POCHECHUEVA T, Chinarev A, Schoetzau A, Fedier A, et al
    Blood Plasma-Derived Anti-Glycan Antibodies to Sialylated and Sulfated Glycans Identify Ovarian Cancer Patients.
    PLoS One. 2016;11:e0164230.
    PubMed     Text format     Abstract available


  80. FEDOSEIENKO A, Wieringa HW, Wisman GB, Duiker E, et al
    Nuclear COMMD1 Is Associated with Cisplatin Sensitivity in Ovarian Cancer.
    PLoS One. 2016;11:e0165385.
    PubMed     Text format     Abstract available


  81. SUN S, Cai J, Yang Q, Zhu Y, et al
    Prognostic Value and Implication for Chemotherapy Treatment of ABCB1 in Epithelial Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2016;11:e0166058.
    PubMed     Text format     Abstract available


  82. PENNINGTON M, Gentry-Maharaj A, Karpinskyj C, Miners A, et al
    Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
    PLoS One. 2016;11:e0165539.
    PubMed     Text format     Abstract available


  83. RASOOL M, Malik A, Basit Ashraf MA, Parveen G, et al
    Evaluation of Matrix Metalloproteinases, Cytokines and Their Potential Role in the Development of Ovarian Cancer.
    PLoS One. 2016;11:e0167149.
    PubMed     Text format     Abstract available


  84. POWELL CD, Paullin TR, Aoisa C, Menzie CJ, et al
    The Heat Shock Transcription Factor HSF1 Induces Ovarian Cancer Epithelial-Mesenchymal Transition in a 3D Spheroid Growth Model.
    PLoS One. 2016;11:e0168389.
    PubMed     Text format     Abstract available


  85. TAO F, Ruan S, Liu W, Wang L, et al
    Fuling Granule, a Traditional Chinese Medicine Compound, Suppresses Cell Proliferation and TGFbeta-Induced EMT in Ovarian Cancer.
    PLoS One. 2016;11:e0168892.
    PubMed     Text format     Abstract available


    January 2015
  86. LI N, Yang L, Wang H, Yi T, et al
    MiR-130a and MiR-374a Function as Novel Regulators of Cisplatin Resistance in Human Ovarian Cancer A2780 Cells.
    PLoS One. 2015;10:e0128886.
    PubMed     Text format     Abstract available


  87. JANATOVA M, Soukupova J, Stribrna J, Kleiblova P, et al
    Mutation Analysis of the RAD51C and RAD51D Genes in High-Risk Ovarian Cancer Patients and Families from the Czech Republic.
    PLoS One. 2015;10:e0127711.
    PubMed     Text format     Abstract available


  88. KWIATKOWSKI F, Arbre M, Bidet Y, Laquet C, et al
    BRCA Mutations Increase Fertility in Families at Hereditary Breast/Ovarian Cancer Risk.
    PLoS One. 2015;10:e0127363.
    PubMed     Text format     Abstract available


  89. CHORNOKUR G, Lin HY, Tyrer JP, Lawrenson K, et al
    Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk.
    PLoS One. 2015;10:e0128106.
    PubMed     Text format     Abstract available


  90. LANG F, Qin Z, Li F, Zhang H, et al
    Apoptotic Cell Death Induced by Resveratrol Is Partially Mediated by the Autophagy Pathway in Human Ovarian Cancer Cells.
    PLoS One. 2015;10:e0129196.
    PubMed     Text format     Abstract available


  91. TUMMERS QR, Hoogstins CE, Peters AA, de Kroon CD, et al
    The Value of Intraoperative Near-Infrared Fluorescence Imaging Based on Enhanced Permeability and Retention of Indocyanine Green: Feasibility and False-Positives in Ovarian Cancer.
    PLoS One. 2015;10:e0129766.
    PubMed     Text format     Abstract available


  92. RAVOORI MK, Nishimura M, Singh SP, Lu C, et al
    Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
    PLoS One. 2015;10:e0131095.
    PubMed     Text format     Abstract available


  93. DU Y, Feng J, Wang R, Zhang H, et al
    Effects of Flavonoids from Potamogeton crispus L. on Proliferation, Migration, and Invasion of Human Ovarian Cancer Cells.
    PLoS One. 2015;10:e0130685.
    PubMed     Text format     Abstract available


  94. ZHOU Y, Bian B, Yuan X, Xie G, et al
    Prognostic Value of Circulating Tumor Cells in Ovarian Cancer: A Meta-Analysis.
    PLoS One. 2015;10:e0130873.
    PubMed     Text format     Abstract available


  95. QIN DJ, Tang CX, Yang L, Lei H, et al
    Hsp90 Is a Novel Target Molecule of CDDO-Me in Inhibiting Proliferation of Ovarian Cancer Cells.
    PLoS One. 2015;10:e0132337.
    PubMed     Text format     Abstract available


  96. BOBBS A, Gellerman K, Hallas WM, Joseph S, et al
    ARID3B Directly Regulates Ovarian Cancer Promoting Genes.
    PLoS One. 2015;10:e0131961.
    PubMed     Text format     Abstract available


  97. MO L, Pospichalova V, Huang Z, Murphy SK, et al
    Ascites Increases Expression/Function of Multidrug Resistance Proteins in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0131579.
    PubMed     Text format     Abstract available


  98. ZHANG S, Lu Z, Mao W, Ahmed AA, et al
    CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.
    PLoS One. 2015;10:e0131833.
    PubMed     Text format     Abstract available


  99. HARAGUCHI M, Sato M, Ozawa M
    CRISPR/Cas9n-Mediated Deletion of the Snail 1Gene (SNAI1) Reveals Its Role in Regulating Cell Morphology, Cell-Cell Interactions, and Gene Expression in Ovarian Cancer (RMG-1) Cells.
    PLoS One. 2015;10:e0132260.
    PubMed     Text format     Abstract available


  100. LEE YC, Lee CH, Tsai HP, An HW, et al
    Targeting of Topoisomerase I for Prognoses and Therapeutics of Camptothecin-Resistant Ovarian Cancer.
    PLoS One. 2015;10:e0132579.
    PubMed     Text format     Abstract available


  101. CHAO A, Tsai CL, Jung SM, Chuang WC, et al
    BAI1-Associated Protein 2-Like 1 (BAIAP2L1) Is a Potential Biomarker in Ovarian Cancer.
    PLoS One. 2015;10:e0133081.
    PubMed     Text format     Abstract available


  102. NIU L, Li S, Liang H, Li H, et al
    The hMLH1 -93G>A Polymorphism and Risk of Ovarian Cancer in the Chinese Population.
    PLoS One. 2015;10:e0135822.
    PubMed     Text format     Abstract available


  103. BELOTTE J, Fletcher NM, Saed MG, Abusamaan MS, et al
    A Single Nucleotide Polymorphism in Catalase Is Strongly Associated with Ovarian Cancer Survival.
    PLoS One. 2015;10:e0135739.
    PubMed     Text format     Abstract available


  104. GRANADOS ML, Hudson LG, Samudio-Ruiz SL
    Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.
    PLoS One. 2015;10:e0136893.
    PubMed     Text format     Abstract available


  105. QIAN X, Qin J, Pan S, Li X, et al
    Maintenance Therapy in Ovarian Cancer with Targeted Agents Improves PFS and OS: A Systematic Review and Meta-Analysis.
    PLoS One. 2015;10:e0139026.
    PubMed     Text format     Abstract available


  106. YUAN C, Liu X, Liu X, Yang N, et al
    The GADD45A (1506T>C) Polymorphism Is Associated with Ovarian Cancer Susceptibility and Prognosis.
    PLoS One. 2015;10:e0138692.
    PubMed     Text format     Abstract available


  107. DEVAPATLA B, Sharma A, Woo S
    CXCR2 Inhibition Combined with Sorafenib Improved Antitumor and Antiangiogenic Response in Preclinical Models of Ovarian Cancer.
    PLoS One. 2015;10:e0139237.
    PubMed     Text format     Abstract available


  108. AUST S, Knogler T, Pils D, Obermayr E, et al
    Skeletal Muscle Depletion and Markers for Cancer Cachexia Are Strong Prognostic Factors in Epithelial Ovarian Cancer.
    PLoS One. 2015;10:e0140403.
    PubMed     Text format     Abstract available


  109. GARZIERA M, Montico M, Bidoli E, Scalone S, et al
    Prognostic Role of Serum Antibody Immunity to p53 Oncogenic Protein in Ovarian Cancer: A Systematic Review and a Meta-Analysis.
    PLoS One. 2015;10:e0140351.
    PubMed     Text format     Abstract available


  110. BENSON EA, Skaar TC, Liu Y, Nephew KP, et al
    Carboplatin with Decitabine Therapy, in Recurrent Platinum Resistant Ovarian Cancer, Alters Circulating miRNAs Concentrations: A Pilot Study.
    PLoS One. 2015;10:e0141279.
    PubMed     Text format     Abstract available


  111. LIU J, Bai J, Jiang G, Li X, et al
    Anti-Tumor Effect of Pinus massoniana Bark Proanthocyanidins on Ovarian Cancer through Induction of Cell Apoptosis and Inhibition of Cell Migration.
    PLoS One. 2015;10:e0142157.
    PubMed     Text format     Abstract available


  112. CHAO WR, Lee MY, Ruan A, Sheng HP, et al
    Assessment of HER2 Status Using Immunohistochemistry (IHC) and Fluorescence In Situ Hybridization (FISH) Techniques in Mucinous Epithelial Ovarian Cancer: A Comprehensive Comparison between ToGA Biopsy Method and ToGA Surgical Specimen Method.
    PLoS One. 2015;10:e0142135.
    PubMed     Text format     Abstract available


  113. WU N, Wei J, Wang Y, Yan J, et al
    Ribosomal L22-like1 (RPL22L1) Promotes Ovarian Cancer Metastasis by Inducing Epithelial-to-Mesenchymal Transition.
    PLoS One. 2015;10:e0143659.
    PubMed     Text format     Abstract available


  114. PATHAK HB, Zhou Y, Sethi G, Hirst J, et al
    A Synthetic Lethality Screen Using a Focused siRNA Library to Identify Sensitizers to Dasatinib Therapy for the Treatment of Epithelial Ovarian Cancer.
    PLoS One. 2015;10:e0144126.
    PubMed     Text format     Abstract available


  115. QIAO JJ, Yu J, Yu Z, Li N, et al
    Contrast-enhanced ultrasonography in differential diagnosis of benign and malignant ovarian tumors.
    PLoS One. 2015;10:e0118872.
    PubMed     Text format     Abstract available


  116. MISHRA EK, Corcoran JP, Hallifax RJ, Stradling J, et al
    Defining the minimal important difference for the visual analogue scale assessing dyspnea in patients with malignant pleural effusions.
    PLoS One. 2015;10:e0123798.
    PubMed     Text format     Abstract available


  117. VERMEERSCH KA, Wang L, Mezencev R, McDonald JF, et al
    OVCAR-3 spheroid-derived cells display distinct metabolic profiles.
    PLoS One. 2015;10:e0118262.
    PubMed     Text format     Abstract available


  118. EULENBURG C, Mahner S, Woelber L, Wegscheider K, et al
    A systematic model specification procedure for an illness-death model without recovery.
    PLoS One. 2015;10:e0123489.
    PubMed     Text format     Abstract available


  119. RAO TD, Tian H, Ma X, Yan X, et al
    Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion.
    PLoS One. 2015;10:e0126633.
    PubMed     Text format     Abstract available


  120. GLASER G, Weroha SJ, Becker MA, Hou X, et al
    Conventional chemotherapy and oncogenic pathway targeting in ovarian carcinosarcoma using a patient-derived tumorgraft.
    PLoS One. 2015;10:e0126867.
    PubMed     Text format     Abstract available


  121. CHEN S, Chen X, Xiu YL, Sun KX, et al
    Inhibition of Ovarian Epithelial Carcinoma Tumorigenesis and Progression by microRNA 106b Mediated through the RhoC Pathway.
    PLoS One. 2015;10:e0125714.
    PubMed     Text format     Abstract available


  122. WANG X, Jiang P, Wang P, Yang CS, et al
    EGCG Enhances Cisplatin Sensitivity by Regulating Expression of the Copper and Cisplatin Influx Transporter CTR1 in Ovary Cancer.
    PLoS One. 2015;10:e0125402.
    PubMed     Text format     Abstract available


  123. KANG J, Lee HJ, Kim J, Lee JJ, et al
    Dysregulation of X chromosome inactivation in high grade ovarian serous adenocarcinoma.
    PLoS One. 2015;10:e0118927.
    PubMed     Text format     Abstract available


  124. LINDEGREN S, Andrade LN, Back T, Machado CM, et al
    Binding Affinity, Specificity and Comparative Biodistribution of the Parental Murine Monoclonal Antibody MX35 (Anti-NaPi2b) and Its Humanized Version Rebmab200.
    PLoS One. 2015;10:e0126298.
    PubMed     Text format     Abstract available


  125. YE S, Yang J, Cao D, Bai H, et al
    Characteristic and prognostic implication of venous thromboembolism in ovarian clear cell carcinoma: a 12-year retrospective study.
    PLoS One. 2015;10:e0121818.
    PubMed     Text format     Abstract available


  126. PATTERSON SD, Rossi JM, Paweletz KL, Fitzpatrick VD, et al
    Functional EpoR pathway utilization is not detected in primary tumor cells isolated from human breast, non-small cell lung, colorectal, and ovarian tumor tissues.
    PLoS One. 2015;10:e0122149.
    PubMed     Text format     Abstract available


  127. DE BOER E, Crane LM, van Oosten M, van der Vegt B, et al
    Folate Receptor-Beta Has Limited Value for Fluorescent Imaging in Ovarian, Breast and Colorectal Cancer.
    PLoS One. 2015;10:e0135012.
    PubMed     Text format     Abstract available


  128. SCHUMMER M, Thorpe J, Giraldez M, Bergan L, et al
    Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer.
    PLoS One. 2015;10:e0142911.
    PubMed     Text format     Abstract available


  129. KENMOGNE LC, Ayan D, Roy J, Maltais R, et al
    The Aminosteroid Derivative RM-133 Shows In Vitro and In Vivo Antitumor Activity in Human Ovarian and Pancreatic Cancers.
    PLoS One. 2015;10:e0144890.
    PubMed     Text format     Abstract available


    January 2014
  130. JONSSON JM, Johansson I, Dominguez-Valentin M, Kimbung S, et al
    Molecular subtyping of serous ovarian tumors reveals multiple connections to intrinsic breast cancer subtypes.
    PLoS One. 2014;9:e107643.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: